The impact of calcineurin inhibitors and mammalian target of rapamycininhibitors on anxiety and depression scores in kidney transplant patients

Conclusion: Our results identified fewer side effects of mTORi-based maintenance immunosuppressive regimens regarding depression and anxiety symptoms compared to CNI-based regimens in kidney transplant patients.

📌 3 Key Takeaways

🎯

Objective & Hypothesis:Background/aim: Depression and anxiety are prevalent symptoms in kidney transplant patients.

📊

Key Findings & Data:Materials and methods: A total of 94 kidney transplant patients were enrolled in the study after exclusion of the patients already taking neuropsychiatric medications or unwilling to participate in the study.

💡

Conclusion & Impact:Conclusion: Our results identified fewer side effects of mTORi-based maintenance immunosuppressive regimens regarding depression and anxiety symptoms compared to CNI-based regimens in kidney transplant patients.

🔬Design:Research Article

📍Scope:Comprehensive Sample

⚙️Variables:Domain Parameters

Abstract

Background/aim: Depression and anxiety are prevalent symptoms in kidney transplant patients. We aimed to evaluate the frequency and the severity of depression and anxiety symptoms in kidney transplant recipients using the Beck Depression Inventory (BDI) and Beck Anxiety Inventory (BAI). The data were compared between the patients on CNI-based and mTORi-based maintenance immunosuppressive regimens. Materials and methods: A total of 94 kidney transplant patients were enrolled in the study after exclusion of the patients already taking neuropsychiatric medications or unwilling to participate in the study. Participants were asked to self-report the inventories. Results: Analysis of data showed that 62 (66%) recipients had BDI scores that indicated depression. The patients on CNI-based regimens (n = 74) had increased total BDI scores compared those on mTORi-based regimens [18 (8.75 28) vs. 6 (5.25 14.25), respectively, P < 0.001]. Regarding BAI scores, 79 patients (84%) had prominent anxiety symptoms. The patients on CNI-based regimens had significantly increased total BAI scores compared to those on mTORi-based regimens [21 (13 30.50) vs. 10.50 (8.25 14.75), respectively, P < 0.001]. Conclusion: Our results identified fewer side effects of mTORi-based maintenance immunosuppressive regimens regarding depression and anxiety symptoms compared to CNI-based regimens in kidney transplant patients.

🔖

Cite This Article

AKOĞLU, H., CANBAKAN, B., OĞUZ, E. G., AYLI, M. D., ERCAN, Z., MERHAMETSİZ, Ö., OKYAY, G. U., GÜRSOY, G. K. (2022). The impact of calcineurin inhibitors and mammalian target of rapamycininhibitors on anxiety and depression scores in kidney transplant patients. Turkish Journal of Medical Sciences, Cilt: 46 - Sayı: 5, 1341–1347. https://ajindex.com/articles/610708

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (14)

Hunsicker LG. A survival advantage for renal transplantation. N Engl J Med. 1999; 341: 1762-1763
Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351: 2715-2729
Nankivell B, Borrow R, Fung Cl, OConnell PJ, Chapman JR, Allen RD. Calcineurin inhibitor nephrotoxicity: Longitudinal assessment by protocol histology. Transplantation 2004; 78: 557-565
Bechstein WO. Neurotoxicity of calcineurin inhibitors: impact and clinical management. Transplant Int 2000; 13: 313-326
Cardinal H, Froidure A, Dandavino R, Daloze P, Hébert MJ, Colette S, Boucher A. Conversion from calcineurin inhibitors to sirolimus in kidney transplant recipients: a retrospective cohort study. Transplant Proc 2009; 41: 3308-3310
Martínez-Sanchis S, Bernal MC, Montagud JV, Candela G, Crespo J, Sancho A, Pallardó LM. Effects of immunosuppressive drugs on the cognitive functioning of renal transplant recipients: a pilot study. J Clin Exp Neuropsychol 2011; 33: 1016-1024
Abbott KC, Agodoa LY, OMalley PG. Hospitalised psychoses after renal transplantation in the United States: incidence, risk factors, and prognosis. J Am Soc Nephrol 2003; 14: 1628-1635
Wada K, Yamada N, Sato T, Suzuki H, Miki M, Lee Y, Akiyama K, Kuroda S. Corticosteroid-induced psychotic and mood disorders: diagnosis defined by DSM-IV and clinical pictures. Psychosomatics 2001; 42: 461-466
Griva K, Hansraj S, Thompson D, Jayasena D, Davenport A, Harrison M, Newman SP. Neuropsychological performance after kidney transplantation: a comparison between transplant types and in relation to dialysis and normative data. Nephrol Dial Transplant 2004; 19: 1866-1874
Lang UE, Heger J, Willbring M, Domula M, Matschke K, Tugtekin SM. Immunosuppression using the mammalian target of rapamycin (mTOR) inhibitor everolimus: pilot study shows significant cognitive and affective improvement. Transplant Proc 2009; 41: 4285-4288
Beck AT, Waed CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561-571
Hisli N. Beck depression inventory of university students on the validity and reliability. J Psychol 1989; 7: 3-13
Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: Psychometric properties. J Consult Clin Psychol 1988; 56: 893-897
Eren I, Sahin M, Tunc SE, Cure E, Civi II. Psychiatric symptoms and quality of life in patients with Behçets disease. Neurol Psychiatr Brain Res 2006;